Validation of an MRI Brain Injury and Growth Scoring System in Very Preterm Infants Scanned at 29- to 35-Week Postmenstrual Age

J.M. George, S. Fiori, J. Fripp, K. Pannek, J. Bursle, R.X. Moldrich, A. Guzzetta, A. Coulthard, R.S. Ware, S.E. Rose, P.B. Colditz, and R.N. Boyd

ABSTRACT

BACKGROUND AND PURPOSE: The diagnostic and prognostic potential of brain MR imaging before term-equivalent age is limited until valid MR imaging scoring systems are available. This study aimed to validate an MR imaging scoring system of brain injury and impaired growth for use at 29 to 35 weeks postmenstrual age in infants born at <31 weeks gestational age.

MATERIALS AND METHODS: Eighty-three infants in a prospective cohort study underwent early 3T MR imaging between 29 and 35 weeks’ postmenstrual age (mean, 32 ± 2 weeks; 49 males, born at median gestation of 28 ± 4 weeks; range, 23.6–30.6 weeks; mean birthweight: 1068 ± 312 g). Seventy-seven infants had a second MR scan at term-equivalent age (mean, 40 ± 7 weeks). Structural images were scored using a modified scoring system which generated WM, cortical gray matter, deep gray matter, cerebellar, and global scores. Outcome at 12-months corrected age (mean, 12 months 4 days ± 1.2 weeks) consisted of the Bayley Scales of Infant and Toddler Development, 3rd ed. (Bayley III), and the Neuro-Sensory Motor Developmental Assessment.

RESULTS: Early MR imaging global, WM, and deep gray matter scores were negatively associated with Bayley III motor (regression coefficient for global score β = −1.31; 95% CI, −2.39 to −0.23; P = .02), cognitive (β = −1.52; 95% CI, −2.39 to −0.65; P < .01) and the Neuro-Sensory Motor Developmental Assessment outcomes (β = −1.73; 95% CI, −3.19 to −0.28; P = .02). Early MR imaging cerebellar scores were negatively associated with the Neuro-Sensory Motor Developmental Assessment (β = −5.99; 95% CI, −11.82 to −0.16; P = .04). Results were reconfirmed at term-equivalent-age MR imaging.

CONCLUSIONS: This clinically accessible MR imaging scoring system is valid for use at 29 to 35 weeks postmenstrual age in infants born very preterm. It enables identification of infants at risk of adverse outcomes before the current standard of term-equivalent age.

ABBREVIATIONS: CA = corrected age; c- = corrected; CGM = cortical gray matter; DGM = deep gray matter; ICC = intraclass correlation coefficient; NSMDA = Neuro-Sensory Motor Developmental Assessment; PMA = postmenstrual age; TEA = term-equivalent age

Preterm infants are at risk of brain injury and impaired brain growth and consequently poorer outcomes in infancy and childhood.1–6 Scoring of structural MR imaging to classify brain injury and growth has been validated for use at term-equivalent age (TEA) in infants born preterm.1–7 Initial systems were qualitative, focusing on classification of the severity of WM and cortical gray matter (CGM) injuries.7,9 The degree of WM abnormality demonstrated significant associations with concurrent motor, neurologic, and neurobehavioral performance10–13 and increases

Clinical Trial Registration: Australian New Zealand Clinical Trials Registry; Trial Registration Number: ACTRN12613000280707; Web address of trial: http://www.anzctr.org.au/ACTRN12613000280707.aspx.

Please address correspondence to Joanne M. George, Queensland Cerebral Palsy and Rehabilitation Research Centre, Centre for Children’s Health Research, The University of Queensland, Level 6, 62 Graham St, South Brisbane, Queensland, 4101, Australia; e-mail: j.george2@uq.edu.au

Indicates article with supplemental on-line tables.

Indicates article with supplemental on-line photos.

http://dx.doi.org/10.3174/ajnr.A5191

These brain metrics correlated with brain volumes and
A reference
Each of
The study aimed to establish predictive validity for mo-
Reduced deep gray matter
and an increased interhemispheric distance indepen-
poorer
Ethics approval was
At TEA, global brain
was used to score all MRIs. An independent neu-
The WM total scores were categorized as none
Reduced biparietal width at TEA predicted both motor and cog-
cognitive outcomes at 2-year CA. Reduced biparietal width at TEA predicted both motor and cog-
nity general movements at 3-month corrected age (CA),
poorer cognitive outcomes at 12-month CA, and poorer motor and cognitive outcomes at 2-year CA. Reduced deep gray matter area at TEA was associated with poorer motor and cognitive outcomes, and an increased interhemispheric distance independently predicted poorer cognitive development at 2-year CA. Reduced deep gray matter scores were significantly associated with poorer cognitive development at 2-year CA. The University of Queensland (2012001060), and the trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12613000280707).

**MR Imaging Acquisition**

Brain MR imaging was performed during sleep without sedation between 30 and 32 weeks PMA or when the infant was medically stable (range, 29 to 35 weeks PMA, early MR imaging) and again at TEA (40 to 42 weeks PMA, term MR imaging). Infants were scanned by using a 3T MR imaging scanner, Tim Trio (Siemens Erlangen, Germany), using an MR compatible incubator with its dedicated neonatal head coil (Nomag incubator; LMT Lammers Medical Technology, Lübeck, Germany). Coronal, axial, and sagittal T2-weighted HASTE (TR/TE, 2000/90 ms; flip angle,150°; FOV, 200 × 160 mm; matrix, 320 × 256; section thickness, 4 mm), axial T1 TSE (TR/TE, 1490/90 ms; flip angle, 150°; FOV, 200 × 160 mm; matrix, 256 × 180; section thickness, 2 mm), and axial multiecho T2 TSE images (TR/TE1/TE2/TE3, 10,580/27/122/189 ms; flip angle, 150°; FOV, 144 × 180 mm; matrix, 204 × 256; section thickness, 2 mm) were acquired.

**MR Imaging Scoring**

A standardized MR imaging scoring system according to Kido oro et al was used to score all MRIs. An independent neurologist with training in radiology and experienced in neonatal MR imaging scoring (S.F.) performed the scoring. The scorer had no knowledge of any clinical characteristics of the infants except PMA at the time of scanning. Scoring was confirmed by a senior neuroradiologist (A.C.). Modifications to scoring cut-points were made by using the term reference data means and SDs. Scor-
ing items and parameters are detailed in On-line Table 1, a scoring proforma is included in On-line Table 2, and On-line Figs 1–18 provide examples of lesion types and regional measurements.

Cerebral WM abnormality was rated on 6 components, with a maximum total score of 15: cystic degeneration, focal signal ab-
normalities, delayed myelination, thinning of the corpus callo-
sum, dilated lateral ventricles, and reduction of WM volume. Myelination of the corpus callosum and posterior limb of the internal capsule was expected by 36-week PMA, so all infants were given a score of 2 for this item on early MR imaging. The CGM was rated on 3 components with a maximum total score of 8: signal abnormality, delayed gyration, and dilated extracerebral CSF space. Cerebellar and DGM abnormalities were rated on sig-
nal abnormality and volume reduction with maximum total scores of 6 for each. A total of WM, CGM, DGM, and cerebellar scores yielded a global brain abnormality score (0 –35). Each of the WM, CGM, DGM, cerebellar, and global scores could be further categorized into no, mild, moderate, or severe brain abnor-
mality categories. The WM total scores were categorized as none (0 –2), mild (3 –4), moderate (5 –6), or severe (≥7) WM abnormalities. Cortical GM, DGM, and cerebellar categories used the follow-
ing total scores: none (0), mild (1), moderate (2), and se-
vore (≥3). Total global scores were classified as normal (0 –3), mild (4 –7), moderate (8 –11), or severe (≥12) brain abnormalities.

Six regional measurements form part of the scoring: thickness of the corpus callosum (genu, body, and splenium), ventricular diameter, biparietal width, interhemispheric distance, DGM area.

**MATERIALS AND METHODS**

**Study Design and Participants**

This prospective cohort study of infants born at <31-weeks gesta-
tional age was conducted at the Royal Brisbane and Women’s Hospital, Brisbane, Australia, between February 2013 and April 2015. Preterm infants were eligible if they had no congenital ab-
normality, and their parents/caregivers were English-speaking who lived within a 200-km radius of the hospital. A reference sample of healthy term-born infants was simultaneously recruited to generate reference values and cut-points for the regional brain measurements that form part of the scoring system. Inclusion criteria for term-born infants were a gestational age at birth of 38–41 weeks; birthweight above the 10th percentile; an uncom-
plicated pregnancy, delivery, and postpartum period; and nor-
mal neurologic examination findings. Ethics approval was obtained from the Royal Brisbane and Women’s Hospital Hu-
man Research Ethics Committee (HREC/12/QRBW/245) and The University of Queensland (2012001060), and the trial was

---

1.4.5,7,14–16

5.21

1.4.21

3.19

7,18

3

12,22

22

22

22

160 mm; matrix, 320

160 mm; matrix, 256

120 mm; matrix, 240

120 mm; matrix, 204

120 mm; matrix, 192

120 mm; matrix, 160

120 mm; matrix, 128

120 mm; matrix, 96

120 mm; matrix, 64

120 mm; matrix, 48

120 mm; matrix, 32

120 mm; matrix, 24

120 mm; matrix, 18

120 mm; matrix, 12

120 mm; matrix, 30

120 mm; matrix, 20

120 mm; matrix, 15

120 mm; matrix, 10

120 mm; matrix, 7
and trans cerebellar diameter. These measurements change with PMA at the time of MR imaging as a result of head and brain growth. To address this change and minimize the risk of confounding, we examined the relationship of each of these measures with PMA at MR imaging to derive a correction method for PMA at MR imaging. The PMA was determined on the basis of the obstetric estimate measure of gestation at delivery. In the preterm group, early and term MR imaging data were pooled for each of the regional measures, and cases with focal brain lesions were removed to ensure that any linear relationship found was the result of age and not confounded by brain injury. For each measure that demonstrated a linear relationship with PMA at MR imaging, the regression coefficient (slope) was used to generate an equation for correction, written as: Corrected Value = Measured Value + Regression Coefficient × (40-PMA at MR Imaging). The correction was then applied to the full cohort. On-line Figs 8–10 and 15 provide instructions for conducting regional measurements, correcting the raw values, and scoring.

The regional measurements were also obtained for the term reference sample, and examination of the relationship with PMA at MR imaging was performed separately from that of the preterm group. When linear relationships were found, measurements were corrected as per the equation above. Following correction of the term reference sample regional scores, means and SDs were calculated, and these were used to create cut-points for scoring each of the respective regional measurements.

Intrarater reproducibility of MR imaging scoring was tested on a separate sample with 20 MR scans from each time point scored by a second blinded rater, a pediatric radiologist (J.B.). Intrarater reproducibility was tested with 20 MR scans from each time point rescored 1 month apart (S.F.).

**Neurodevelopmental Outcome at 12-Months CA**

All infants underwent neurodevelopmental assessment at 12-months CA by an experienced physiotherapist blinded to MR imaging findings and medical history. The Bayley Scales of Infant and Toddler Development, 3rd ed. (Bayley III), was performed, and composite scores for motor and cognitive performance were generated. The Neuro-Sensory Motor Developmental Assessment (NSMDA) evaluates neurologic and sensory motor function in addition to gross and fine motor performance, with total scores and functional classifications used. The NSMDA at 12-months CA has good predictive validity for motor and cognitive outcomes and cerebral palsy at 4-years CA for very preterm infants and 24-month motor and functional outcomes for infants with cerebral palsy.

**Statistical Analysis**

Sample size calculations were based on qualitative evaluation of MR images at TEA predicting 12-month outcomes, with 69 infants required to reject the null hypothesis with 90% power (at P < .05). A sample of 80 infants was recruited to account for attrition and the earlier PMA at MR imaging (29 to 35 weeks PMA).

The association between each of the 6 regional measurements and PMA at MR imaging was analyzed by using mixed-effects regression models for the preterm sample data and separately for the term reference sample data with linear regression. When a linear relationship was found, data were centered around the mean and the relationship was examined to determine whether it was quadratic. Correction equations were then applied to the raw regional measures. Term reference sample mean and SD data were used to generate scoring cut-points for each of the regional measures. Paired t tests were used to determine statistically significant differences between early and term MR imaging item scores in the preterm group.

The association between early MR imaging scores and 12-month outcomes and term MR imaging scores and 12-month outcomes was evaluated with univariable and multivariable linear regression. Multivariable regression included potential confounders of sex, social risk, and, for the NSMDA only, CA at assessment.

To examine the predictive validity of both early and term MR imaging, we calculated sensitivity, specificity, and accuracy (percentage of cases correctly classified). Dichotomized MR imaging and outcome data were used to construct 2 × 2 tables. MR imaging category scores were dichotomized into normal/mild or moderate/severe categories for each of the subscales and global scores. Bayley motor and cognitive composite scores were dichotomized (by < −1 SD) and the NSMDA functional classification scores, as normal/minimal versus mild/moderate/severe/profound.

Inter- and intrarater reliability was evaluated by using intraclass correlation coefficients (ICCs) (type 3, 1). Agreement was evaluated by using the percentage level of accuracy, in which the definition for accuracy was exact score ± 1 for the subscale scores and exact score ± 2 for the global scores.

When we investigated perinatal risk factors, differences across global brain abnormality score categories were determined by using Mann-Whitney U tests (dichotomous perinatal risk factors) and Kruskal Wallis 1-way ANOVAs (continuous perinatal risk factors). Analysis was performed by using the STATA statistical package, Version 14 (StataCorp, College Station, Texas).

**RESULTS**

**Participants**

Of 214 eligible preterm infants, parents or guardians of 110 consented to the study, of whom 83 had early MR imaging and 12-month outcomes available and were included in this analysis (16 with no early MR imaging: 5 medically unstable, 1 death, 4 cancellations due to MR imaging equipment failure, 3 with no MR imaging slots, 1 withdrawn, 2 with movement artefacts; 11 failed to return for 12-month follow-up). Of these, 77/83 had a second MR scan at term. Thirty-eight term-born infants were included in the reference sample. Demographic data and MR imaging scores are summarized in Tables 1–3; 12-month outcomes are summarized in Table 4. There were minimal differences between those participants with both early and term MR imaging and those with only early MR imaging, except that all 6 participants who did not undergo their term MR imaging were classified with a higher social risk. Given the established relationship between higher social risk and poorer neurodevelopmental outcome and an increased risk of cerebral palsy and to address this difference in our cohort between early and term MR imaging, all multivariable analyses included social risk as a potential confounder. All term reference sample infants had a normal global brain abnormality category score.
### Table 1: Characteristics of preterm samples and term reference sample

<table>
<thead>
<tr>
<th>Birth and Maternal Data</th>
<th>Full Preterm Sample with Early MRI (n = 83)</th>
<th>Preterm Sample with Additional Term MRI (n = 77)</th>
<th>Term Reference Sample (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight (g)</td>
<td>1068 (32), 494–1886</td>
<td>1076 (32), 494–1886</td>
<td>3509 (317), 2932–4330</td>
</tr>
<tr>
<td>Birth head circumference (cm)</td>
<td>25.62 (2.38), 20.5–30.5, n = 80</td>
<td>25.64 (2.43), 20.5–30.5, n = 75</td>
<td>34.7 (1.12), 32.5–37, n = 31</td>
</tr>
<tr>
<td>Males</td>
<td>49 (59%)</td>
<td>46 (60%)</td>
<td>19 (50%)</td>
</tr>
<tr>
<td>Multiple births</td>
<td>24 (29%)</td>
<td>21 (27%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Premature rupture of membranes</td>
<td>19 (23%)</td>
<td>18 (23%)</td>
<td>4 (12%) n = 33</td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>60 (72%)</td>
<td>56 (73%)</td>
<td>9 (27%) n = 33</td>
</tr>
<tr>
<td>Chorioamnionitis</td>
<td>14 (17%)</td>
<td>13 (17%)</td>
<td></td>
</tr>
<tr>
<td>Antenatal steroids</td>
<td>62 (75%)</td>
<td>57 (74%)</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulphate</td>
<td>43 (65%), n = 66</td>
<td>41 (65%), n = 63</td>
<td></td>
</tr>
<tr>
<td>Higher social risk</td>
<td>40 (48%)</td>
<td>34 (44%)</td>
<td>5 (16%) n = 31</td>
</tr>
</tbody>
</table>

Note: IQR indicates interquartile range.

*Early MRI, 29 to 35 weeks PMA; term MRI, 40 to 42 weeks PMA. Data are No. (%), median [IQR] or mean (SD), range.

### Table 2: Characteristics of preterm samples and term reference sample

<table>
<thead>
<tr>
<th>Acquired Medical Factors</th>
<th>From Birth to Early MRI (n = 83)</th>
<th>From Birth to Term MRI (n = 77)</th>
<th>Term Reference Sample (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patent ductus arteriosus</td>
<td>39 (47%)</td>
<td>36 (47%)</td>
<td></td>
</tr>
<tr>
<td>IVH</td>
<td>17 (20%)</td>
<td>16 (21%)</td>
<td></td>
</tr>
<tr>
<td>IVH grade 3 or 4</td>
<td>4 (5%)</td>
<td>4 (5%)</td>
<td></td>
</tr>
<tr>
<td>Periventricular leukomalacia</td>
<td>2 (2%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>2 (2%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>NEC diagnosed or suspected</td>
<td>3 (4%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>Confirmed sepsis</td>
<td>3 (4%)</td>
<td>2 (3%)</td>
<td></td>
</tr>
<tr>
<td>Total parenteral nutrition (days)</td>
<td>11 [8–14], 0–30</td>
<td>11 [8–14], 0–30</td>
<td></td>
</tr>
<tr>
<td>Postnatal corticosteroids</td>
<td>14 (17%)</td>
<td>14 (18%)</td>
<td></td>
</tr>
<tr>
<td>Ventilation (days)</td>
<td>3 [0–12], 0–48</td>
<td>2 [0–12], 0–48</td>
<td></td>
</tr>
<tr>
<td>CPAP (days)</td>
<td>15 [7–25], 0–47</td>
<td>30 [7–47], 0–81</td>
<td></td>
</tr>
<tr>
<td>Oxygen therapy (hr)</td>
<td>12 [1–125], 0–151</td>
<td>29 [2–370], 0–3912, n = 67</td>
<td></td>
</tr>
<tr>
<td>36-week PMA O2 requirement</td>
<td>23 (30%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMA at MRI (wk)</td>
<td>32 ± 2 (7–13), 29–35–35–2</td>
<td>40 ± 6 (11–13), 38–46–4</td>
<td>41 ± 3 (11), 39–44</td>
</tr>
<tr>
<td>Weight at MRI (g)</td>
<td>1500 (352), 883–2715</td>
<td>1505 (359), 883–2715</td>
<td>3428 (378), 2500–4200, n = 31</td>
</tr>
</tbody>
</table>

Note: IVH indicates intraventricular hemorrhage; NEC, necrotizing enterocolitis; CPAP, continuous positive airway pressure.

*Data are No. (%), median [IQR] or mean (SD), range. Early MRI, 29 to 35 weeks PMA; term MRI, 40 to 42 weeks PMA.

### Table 3: Characteristics of preterm sample and term reference sample

<table>
<thead>
<tr>
<th>MRI Scores</th>
<th>Early MRI</th>
<th>Term MRI</th>
<th>Term Reference Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>White matter</td>
<td>3 [2–4]</td>
<td>1 [1–3]</td>
<td>0 [0–0]</td>
</tr>
<tr>
<td>Cortical gray matter</td>
<td>0 [0–1]</td>
<td>0 [0–1]</td>
<td>0 [0–0]</td>
</tr>
<tr>
<td>Deep gray matter</td>
<td>0 [0–1]</td>
<td>0 [0–1]</td>
<td>0 [0–0]</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>0 [0–0]</td>
<td>0 [0–0]</td>
<td>0 [0–0]</td>
</tr>
</tbody>
</table>

Note: IQR indicates interquartile range.

*Early MRI, 29 to 35 weeks PMA; term MRI, 40 to 42 weeks PMA. Data are median [IQR].

### Table 4: Bayley III and NSMDA scores at 12-month corrected age (n = 83)

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at assessment</td>
<td>12 months 4 days (1–2 wk)</td>
</tr>
<tr>
<td>Bayley III motor composite</td>
<td>96.96 (14.27)</td>
</tr>
<tr>
<td>Bayley III cognitive composite</td>
<td>104.64 (12.07)</td>
</tr>
<tr>
<td>NSMDA total</td>
<td>179.53 (18.81)</td>
</tr>
<tr>
<td>12-mo outcomes dichotomized (No.) (%)</td>
<td></td>
</tr>
<tr>
<td>Bayley III motor composite &lt; −1 SD</td>
<td>15 (18%)</td>
</tr>
<tr>
<td>Bayley III cognitive composite &lt; −1 SD</td>
<td>6 (7%)</td>
</tr>
<tr>
<td>NSMDA functional classification &lt; 2</td>
<td>7 (8%)</td>
</tr>
</tbody>
</table>

*Data are median [IQR].

### Associations between Regional Brain Measurements and PMA at MR Imaging

All preterm regional measures except the body of the corpus callosum demonstrated linear relationships with PMA at MR imaging (P < .01). In the term reference sample, linear relationships were found only for transcerebellar diameter and the genu of the corpus callosum. Results of regression analyses and corrected regional measures for the early, term, and term reference sample MRIs are presented in On-line Tables 3 and 4.

**Findings in Each Scoring Domain at Early and Term MR Imaging**

Results for scoring items are presented in On-line Table 1. The incidence of WM cystic lesions, CGM signal abnormality, and WM volume reduction as measured by corrected biparietal width remained stable between early and term MR imaging. A proportion of signal abnormalities in the WM and DGM resolved between early and term MR imaging. A propensity to score worse at term compared with early MR imaging was evidenced for each of the following: ventricular dilation, interhemispheric distance, volume reduction of the DGM and cerebellum, and thinning of the corpus callosum. More infants had delayed gyral maturation at early MR imaging compared with term MR imaging.

**Predictive Validity of Early MR Imaging**

Results of univariable and multivariable regression analyses between early MR imaging scores and neurodevelopmental outcomes are presented in Fig 1 (first row); sensitivity, specificity, and accuracy, in Table 5. Global, WM, and DGM scores on early...
MR imaging were associated with Bayley III motor outcome multivariably (global score: $\beta = -1.31; 95\% CI, -2.39$ to $-0.23; P = .02$). Early MR imaging WM, DGM, and global scores were associated with Bayley III cognitive outcome (global $\beta = -1.52; 95\% CI, -2.39$ to $-0.65; P < .01$). Early MR imaging WM, DGM, cerebellar, and global scores were associated with outcome on the NSMDA (global $\beta = -1.73; 95\% CI, -3.19$ to $-0.28; P = .02$). The sensitivity of early MR imaging global scores to predict motor, cognitive, and NSMDA outcomes ranged from 33% to 50%, specificity ranged from 86% to 87%, with the percentage of accurately classified cases ranging from 77% to 83%.

Predictive Validity of Term MR Imaging

Univariable and multivariable regression analyses between term MR imaging scores and neurodevelopmental outcomes are presented in Table 5. At term MR imaging, WM, DGM, cerebellar, and global scores were associated with Bayley III motor and cognitive and NSMDA scores. Global scores were associated with Bayley III motor outcome ($\beta = -1.71; 95\% CI, -2.63$ to $-0.79; P < .01$), cognitive outcome ($\beta = -1.32; 95\% CI, -2.10$ to $-0.53; P < .01$), and NSMDA ($\beta = -2.36; 95\% CI, -3.62$ to $-1.10; P < .01$). The sensitivity of term MR imaging global scores to predict motor, cognitive, and NSMDA outcomes ranged from 14% to 33%, specificity ranged from 90% to 92%, with the percentage of accurately classified cases ranging from 77% to 87%.

Inter- and Intrarater Reproducibility

Reliability and agreement results are presented in On-line Table 5. At Early MR imaging, intrarater reliability ranged from 0.82 to 0.97 (ICC), and agreement, from 90% to 100%. Interrater reliability was low for CGM (ICC = 0.08) but excellent for the other...
and a low false-positive rate is preferable to pro-
soso evaluation of the rela-
Their outcome was at
A
MR imaging. In addition, term MR imaging cerebellar scores were
months CA. Early cerebellar scores were also associated with the
global brain abnormality scores were associated with Bayley III
week gestational age is valid. Early MR imaging WM, DGM and
imaging for use at 29 to 35 weeks PMA for infants born at
DISCUSSION
This clinically accessible scoring system of structural brain MR
aging for use at 29 to 35 weeks PMA for infants born at <31-
Week MR imaging WM, DGM and
global brain abnormality scores were associated with Bayley III
motor and cognitive scores and outcome on the NSMDA at 12-
months CA. Early cerebellar scores were also associated with the
NSMDA outcome. These associations were reconfirmed at
imaging. In addition, term MR imaging cerebellar scores were
associated with Bayley III motor and cognitive outcomes.

Early MR imaging was more strongly associated with cognitive
than motor outcomes. The scoring system on which this study
was based has been used in 2 studies examining the relationships
between TEA MR imaging and cognitive outcomes at 7 years.24,25
Our results support previous findings at TEA and suggest that the
brain changes associated with adverse cognitive outcomes are al-
ready present as early as 29 to 35 weeks PMA.7

Of all MR imaging subscale scores, at early and term MR im-
ing, DGM demonstrated the strongest relationship with out-
come. This finding supports inclusion of DGM evaluation in
qualitative and semiquantitative scoring systems in this popu-
lation. Cerebellar scores on early MR imaging were associated with
NSMDA scores but not the Bayley III motor score. This finding is
interesting because the Bayley III motor scale focuses on motor
achievement, while the NSMDA evaluates the quality of motor
performance, including balance and postural reactions, functions
known to be modulated by the cerebellum. The NSMDA also
includes assessment of muscle tone, reflexes, and sensory motor
function, and at 12 months CA, has been shown to predict motor
and cognitive outcomes and cerebral palsy at 4 years in preterm
infants.33,34

The specificity of the scoring system is reasonable, indicating
that those infants whose global scoring category is moderate or
severe have a high probability of poor motor and cognitive out-
comes at 12-months CA. The sensitivity is relatively low, so not all
infants who progress to poor motor and cognitive outcomes will
be identified by this scoring system at early or term MR imaging;
however, it also means that the risk of false-positives is low. Par-
ents indicate a desire for prognostication and early identification
of outcomes,40 and a low false-positive rate is preferable to pro-
longed distress of a false-positive result causing parents to spend
years waiting for an adverse outcome that does not occur.41,42
A combination of TEA MR imaging findings and 3-month CA gen-
eral movement assessment demonstrates improved predictive
validity over TEA MR imaging alone.43-45 so evaluation of the
relationships between this early MR imaging scoring system and
concurrent clinical measures and the combination of early MR
imaging and clinical measures to predict later outcomes is
warranted.

Our results indicate that term MR imaging scores demonstrate
stronger associations with 12-month outcomes than early MR
imaging scores. Term MR imaging associations described here are
stronger than those found by another group using the original
scoring system23; this finding suggests that the modified scoring
cut-points, based on term-born reference sample data, may be an
improvement over the original scale.27 Their outcome was at
2-years CA rather than 12-months CA in the present study. Stron-
ger associations of term MR imaging with outcomes may be due to
small focal lesions evident on early MR imaging having re-
solved by term MR imaging or volume reduction becoming more
apparent. Both of these require further exploration. Term MR
imaging scores presented here show a lower incidence of myeli-
nation delay compared with the cohort on which the scale was
originally based. In the present study, the T1 sequence was per-
formed at the end of the MR imaging when infants were often
beginning to wake up; therefore, it had a higher incidence of mo-
ton artefacts. For this reason, T2-weighted images were used to
to score myelination delay with their improved contrast, and this
may have resulted in an overestimation of myelination compared
with the earlier study.22

CONCLUSIONS
This study presents a clinically accessible MR imaging scoring
system of brain injury and growth for use from 29 to 35 weeks’
PMA in infants born at <31-week gestational age that has good
reproducibility and significant associations with motor and cog-
nitive outcomes at 12-months CA. The tool is suitable for use in
research and for assisting clinical patient management.

ACKNOWLEDGMENTS
We acknowledge the families of infants who participated in this
study; the staff of the neonatal unit and department of medical
imaging; study personnel Dr Melissa Lai, Donna Hovey, Kellie
McGrory, Kylie Smart, Christine Finn, and Kym Morris; and Dr
Francisco Perales for statistical support.

Disclosures: Joanne M. George—RELATED: Grant: University of Queensland Re-
search Scholarship. Comments: This is a PhD living stipend (June 2012 to December
2016). I also received a scholarship from the Queensland Government from June 2012
to December 2015 (Smart State PhD Scholarship). I was awarded a Health Practitio-
ners Research Grant (Queensland Government), which provided funds to support
the broader PPREMO study. Support for Travel to Meetings for the Study or Other
Purposes: University of Queensland, Comments: support for travel to conferences;
Other: grants provided to support the PPREMO Study. Comments: grants from the
Cerebral Palsy Alliance Research Foundation [IRG013], the Financial Markets Founda-
tion for Children [2014-074], and the Queensland Government [Smart State; Health
Practitioner Stimulus Grant] to support this project. The PPREMO study is the
broad project, a prospective cohort study, of which the current work is a part.*

REFERENCES


35. MacDonald J, Burns Y. Performance on the NSMDA during the first
and second year of life to predict functional ability at the age of 4 in children with cerebral palsy. Hong Kong Physiotherapy J 2005;23:40–45 CrossRef


